Treatment discontinuation and switching of antipsychotics among adult patients with schizophrenia in the United States
Schizophrenia Research · 2025
DOI: 10.1016/j.schres.2025.07.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Schizophrenia Research, 2025. Verfasst von Rezaul Khandker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, NJ, USA. Electronic address: rezaul.khandker@merck.com. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents, Drug Substitution, Weight Gain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp and Dohme United Kingdom.
Abstract (Originalsprache)
BACKGROUND: Patients with schizophrenia commonly experience treatment discontinuation/switching, which can result in relapse and high healthcare burden. This study examined associations between antipsychotic discontinuation/switching and weight gain risk (WGR), patient-level characteristics and treatment modalities, including oral antipsychotic (OA) versus long-acting injectable (LAI). METHODS: This retrospective cohort study identified adults diagnosed with schizophrenia, filling an antipsychotic prescription between 1/1/2017-12/31/2019 using the Merative® MarketScan® Multi-State Medicaid administrative claims database. The index date was the first antipsychotic prescription fill date following schizophrenia diagnosis. Associations with discontinuation (≥60-day gap in therapy) and switching (antipsychotic change) were assessed using Kaplan Meier and multivariate Cox proportional hazard regression. RESULTS: Among 6987 patients, 16.8 %, 63.2 %, and 20.0 %, respectively, were indexed on low, medium, and high WGR antipsychotics, while 33.5 % received LAI and 66.5 % OA. More patients on low WGR discontinued than those on medium and high WGR antipsychotics (17.8 % vs. 12.5 % and 12.0 %, respectively, p < 0.001). More patients on OA versus LAI (16.8 % vs. 6.4 %, p < 0.001) discontinued. Time-to-discontinuation was significantly longer on LAI vs. OA (249.5 vs. 90.0 days, p < 0.001). More patients on medium (52.3 %) and high (54.9 %) WGR switched than on low WGR antipsychotics (46.1 %) (p < 0.001). Patients on LAI antipsychotics had half the hazard of discontinuation (hazard ratio [HR]: 0.53; 95 % CI: 0.47-0.59, p < 0.001) than on OA. CONCLUSIONS: Discontinuation occurred more frequently among patients taking OAs, while switching occurred more frequently among patients taking higher WGR antipsychotics. Schizophrenia treatment is complex and needs effective treatment options with increased treatment persistence to reduce disease burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc., Rahway, NJ, USA. Electronic address: rezaul.khandker@merck.com.
- Merck & Co., Inc., Rahway, NJ, USA.
- OPEN Health, New York, NY, USA.
Förderung
- Merck Sharp and Dohme United Kingdom
Zitieren
APA
Khandker, R., Mohit, B., Fonseca, E., Fleming, S., Tan, M., Quan, W., LeMasters, T., & Schmier, J. (2025). Treatment discontinuation and switching of antipsychotics among adult patients with schizophrenia in the United States. Schizophrenia Research. https://doi.org/10.1016/j.schres.2025.07.017
Vancouver
Khandker R, Mohit B, Fonseca E, Fleming S, Tan M, Quan W, et al. Treatment discontinuation and switching of antipsychotics among adult patients with schizophrenia in the United States. Schizophrenia Research. 2025. doi:10.1016/j.schres.2025.07.017
BibTeX
@article{Khandker2025,
author = {Khandker, Rezaul and Mohit, Babak and Fonseca, Eileen and Fleming, Sean and Tan, Malinda and Quan, Wenying and LeMasters, Traci and Schmier, Jordana},
title = {Treatment discontinuation and switching of antipsychotics among adult patients with schizophrenia in the United States},
journal = {Schizophrenia Research},
year = {2025},
doi = {10.1016/j.schres.2025.07.017}
}
EUVIMED